Glucagon-like peptide 1 receptor agonists (GLP-1RAs), traditionally used in the treatment of type 2 diabetes, are becoming increasingly appreciated for their diverse applications
Check Out Our 5 Star Reviews Additional Services You May Like Botox Emsculpt Smartlipo Lip Fillers Liposuction HydraFacial Microneedling Skin Assessment Microdermabrasion Skin Rejuvenation Laser Hair Removal Chemical Peels Nonsurgical Vaginal Tightening 360 Liposuction Laser Liposuction Cynosure Picosure laser Daxxify IV Hydration DRIPBaR IV Therapy The DRIPBaR Infrared Sauna Steam Sauna Cold Plunges Heated Plunges Normatec Compressions Emtone O-Shot Juvederm Kybella SkinTyte Ultherapy BioTE Hormone Replacement Therapy Laser Vein Removal Hair Treatment Laser Tattoo Removal Laser Skin Resurfacing Microneedling Broadband Light Therapy Medical Weight Loss Vivace ShenB Cartessa Microneedling IV Therapy for Recovery Nutrition Aescape Massage Zero Gravity Massage Chairs Whole Body Cryotherapy Red Light Therapy Bed HBOT Hyperbaric Chamber Aescape AI Robotic Massage Chin Liposuction
Watch for Undereating One of the biggest real-world risks with GLP-1style treatment is not just eating less, but eating too little of the right things
But the top line results remain exciting.
Regarding renal outcomes, GLP-1RAs were associated with a lower risk of kidney-specific composite outcomes, nephropathy, and albuminuria, although certainty was low
The effect was functionally similar to a coverage removal, as the barriers to approval became high enough that many patients could not navigate the process successfully
